The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. (October 2020) - Hong, N.H.; Le Moigne, R.; Pearson, P.; Lauriault, V.; Banuelos, C.A.; Mawji, N.R.; Tam, T.; Wang, J.; Virsik, P.; Andersen, R.J.; Sadar, M.D.; Zhou, H.J.; et al.